About us

Focus What are iPS Cells? An induced pluripotent Stem cell (or iPS cell) is an adult cell that has been reprogrammed to...	Multimedia
Latest press releases 23/10/2012 : Cellectis bioresearch Inc. wins a $6.9 million... 02/04/2012 : Appointment of Mathieu Simon, MD, to the position... 13/02/2012 : Cellectis announces the redemption of the bonds...	Contacts Cellectis, Biopark 8 rue de la Croix Jarry 75013 Paris / FRANCE media@cellectis.com Phone : +33 (0)1 81 69 16 00

Worldwide pioneer in Genome engineering
Established in 1999, listed on the NYSE-Euronext Alternext market in Paris since 2007
Revenues 2011: €19 M (73% sales from abroad)
Staff: 220 including 74 PhDs
4 subsidiaries: Cellectis bioresearch, Cellectis therapeutics, Ectycell, Cellectis plant sciences and a business unit: Cellectis stem cells composed of Ectycell & Cellartis
Applications: human health, research and biomanufacturing, agrobiotechnology, stem cells
Main technologies: Genome engineering, Protein engineering
IP portfolio: 83 patents granted plus over 300 pending
Location: Paris (France), Evry (France), Saint-Paul, Minnesota (USA), Cambridge, Massachusetts (USA), Goteborg (Sweden)

Subsidiaries